Table 1.

Clinical features of CD20+ PTCL-NOS.

Case	Age	Sex	Clinical presentation	B symptoms	ECOG	Stage	IPI score	BM involvement	LDH	Treatments and response	Follow-up
1	69	Male	Abdominal distension, splenomegaly	Present	1	IV	2	Present (Bone marrow biopsy)	215U/L	CHOPE×2(PR), Unclear	Alive, PFS:23m, OS:23m
2	48	Male	Splenomegaly	Absent	0	IV	1	Present (Bone marrow biopsy)	184U/L	CHOP×1,CHOPE×3(SD),BV+CHPE×2(SD),Azacitidine+Chidamide,Azacitidine+Chidamide+BTZ+CTX(SD),BR(SD)	Alive, PFS:14m, OS:14m
3	61	Female	Chest distress, cough, mediastinal mass	Absent	1	IV	1	Present (PET/CT)	240U/L	CHOPE×4(SD),GemoxD×2, Radiotherapy (PR),R-Gemox-D×4(PR),Azacitidine+Chidamide(PD)	Alive, PFS:14m, OS: 16m

ECOG, Eastern Cooperative Oncology Group performance; IPI, International Prognostic Index; BM, bone marrow; LDH, lactic dehydrogenase; C, cyclophosphamide; H, doxorubicin; O, vincristine; P, prednisone E, etoposide; BV, brentuximab vedotin; BTZ, bortezomib; BR, bendamustine, rituximab; GemoxD, gemcitabine, oxaliplatin, dexamethasone; R, rituximab; PR, partial remission; SD, stable disease; PD, progressive disease; m, months.